Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| ABBOTT LABORATORIESABT · Entity 2314 | Executive Vice President | August 07, 2007 | August 09, 2007 |
| ASHLAND INC.ASH · Entity 4139 | Director | December 30, 2022 | January 05, 2023 |
| LANDAUER INCLDR · Entity 172389 | Director | October 19, 2017 | October 19, 2017 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
ABBOTT LABORATORIES
Report date August 07, 2007 · Filed August 09, 2007
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common shares without par valueSEC Table I · non-derivative | Direct | 237,413 |
Ending reported balance
After 2007-08-08 transaction · row 6
6 source rows · reconciled sequenceRow 1 · 2007-08-07 · Exercise / conversion · Acquired 17,053 · Balance 238,082 Row 2 · 2007-08-07 · Exercise / conversion · Acquired 11,006 · Balance 249,088 Row 3 · 2007-08-07 · Tax withholding · Disposed 24,269 · Balance 224,819 Row 4 · 2007-08-08 · Exercise / conversion · Acquired 72,130 · Balance 296,949 Row 5 · 2007-08-08 · Exercise / conversion · Acquired 24,247 · Balance 321,196 Row 6 · 2007-08-08 · Tax withholding · Disposed 83,783 · Balance 237,413 |
| Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $41.03 · Expires 2014-02-19 | Direct | 2,454 |
Reported balance
After 2007-08-07 transaction · row 8
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 8 · 2007-08-07 · Exercise / conversion · Disposed 17,053 · Balance 2,454 F2: Employee stock option, including replacement option feature granted pursuant to the Abbott Laboratories 1996 Incentive Stock Program in a transaction exempt from Section 16(b) under Rule 16b-3. |
| Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $41.64 · Expires 2013-02-13 | Direct | 0 |
Reported balance
After 2007-08-07 transaction · row 9
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 9 · 2007-08-07 · Exercise / conversion · Disposed 11,006 · Balance 0 F2: Employee stock option, including replacement option feature granted pursuant to the Abbott Laboratories 1996 Incentive Stock Program in a transaction exempt from Section 16(b) under Rule 16b-3. |
| Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $53.12 · Expires 2014-02-19 | Direct | 14,703 |
Reported balance
After 2007-08-07 transaction · row 10
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 10 · 2007-08-07 · Grant · Acquired 14,703 · Balance 14,703 F2: Employee stock option, including replacement option feature granted pursuant to the Abbott Laboratories 1996 Incentive Stock Program in a transaction exempt from Section 16(b) under Rule 16b-3. |
| Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $53.12 · Expires 2013-02-13 | Direct | 9,566 |
Reported balance
After 2007-08-07 transaction · row 11
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 11 · 2007-08-07 · Grant · Acquired 9,566 · Balance 9,566 F2: Employee stock option, including replacement option feature granted pursuant to the Abbott Laboratories 1996 Incentive Stock Program in a transaction exempt from Section 16(b) under Rule 16b-3. |
| Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $42.50 · Expires 2009-02-11 | Direct | 2,353 |
Reported balance
After 2007-08-08 transaction · row 12
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 12 · 2007-08-08 · Exercise / conversion · Disposed 72,130 · Balance 2,353 F2: Employee stock option, including replacement option feature granted pursuant to the Abbott Laboratories 1996 Incentive Stock Program in a transaction exempt from Section 16(b) under Rule 16b-3. |
| Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $42.83 · Expires 2013-02-13 | Direct | 3,081 |
Reported balance
After 2007-08-08 transaction · row 13
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 13 · 2007-08-08 · Exercise / conversion · Disposed 24,247 · Balance 3,081 F2: Employee stock option, including replacement option feature granted pursuant to the Abbott Laboratories 1996 Incentive Stock Program in a transaction exempt from Section 16(b) under Rule 16b-3. |
| Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $54.30 · Expires 2009-02-11 | Direct | 62,637 |
Reported balance
After 2007-08-08 transaction · row 14
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 14 · 2007-08-08 · Grant · Acquired 62,637 · Balance 62,637 F2: Employee stock option, including replacement option feature granted pursuant to the Abbott Laboratories 1996 Incentive Stock Program in a transaction exempt from Section 16(b) under Rule 16b-3. |
| Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $54.30 · Expires 2013-02-13 | Direct | 21,146 |
Reported balance
After 2007-08-08 transaction · row 15
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 15 · 2007-08-08 · Grant · Acquired 21,146 · Balance 21,146 F2: Employee stock option, including replacement option feature granted pursuant to the Abbott Laboratories 1996 Incentive Stock Program in a transaction exempt from Section 16(b) under Rule 16b-3. |
| Common shares without par valueSEC Table I · non-derivative | IndirectProfit Sharing Trust | 10,694 |
Reported balance
Holding disclosure · report date 2007-08-07 · row 7
Holding and transaction disclosures are not merged.
1 source rowRow 7 · Balance 10,694 F1: Balance in the Abbott Laboratories Stock Retirement Trust as of August 7, 2007. |
Filing footnotes · ownership attribution and instrument terms
F1: Balance in the Abbott Laboratories Stock Retirement Trust as of August 7, 2007.
F2: Employee stock option, including replacement option feature granted pursuant to the Abbott Laboratories 1996 Incentive Stock Program in a transaction exempt from Section 16(b) under Rule 16b-3.
ASHLAND INC.
Report date December 30, 2022 · Filed January 05, 2023
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common Stock UnitsSEC Table II · derivative / convertible security | Direct | 2,854 |
Reported balance
After 2022-12-30 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2022-12-30 · Other · Disposed 267 · Balance 2,854 F1: 1 for 1 F2: Common Stock Units acquired pursuant to Ashland's Deferred Compensation Plan for Non-Employee Directors (the "Plan") and exempt under Rule 16b-3. (One (1) Common Stock Unit in the Plan is the equivalent of one (1) share of Ashland Common Stock.) F3: Subject to any deferral election on timing of distribution by the reporting person under the Plan, the Common Stock Units are payable in Common Stock upon the reporting person's separation from service as a director. |
Filing footnotes · ownership attribution and instrument terms
F1: 1 for 1
F2: Common Stock Units acquired pursuant to Ashland's Deferred Compensation Plan for Non-Employee Directors (the "Plan") and exempt under Rule 16b-3. (One (1) Common Stock Unit in the Plan is the equivalent of one (1) share of Ashland Common Stock.)
F3: Subject to any deferral election on timing of distribution by the reporting person under the Plan, the Common Stock Units are payable in Common Stock upon the reporting person's separation from service as a director.
LANDAUER INC
Report date October 19, 2017 · Filed October 19, 2017
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2017-10-19 transaction · row 1
1 source rowRow 1 · 2017-10-19 · Disposition to issuer · Disposed 20,019 · Balance 0 F1: Pursuant to an Agreement and Plan of Merger, dated September 6, 2017 (the ?Merger Agreement?), by and among Fern Merger Sub Inc., a Delaware corporation (?Purchaser?) and an indirect wholly owned subsidiary of Fortive Corporation, a Delaware corporation, and Landauer, Inc., a Delaware corporation (the ?Issuer?), each outstanding share of the Issuer?s common stock was disposed of pursuant to the closing on October 19, 2017 of a cash tender offer by Purchaser to acquire common stock of Issuer in exchange for $67.25 per share in cash, subject to any required withholding of taxes, without interest. |
Filing footnotes · ownership attribution and instrument terms
F1: Pursuant to an Agreement and Plan of Merger, dated September 6, 2017 (the ?Merger Agreement?), by and among Fern Merger Sub Inc., a Delaware corporation (?Purchaser?) and an indirect wholly owned subsidiary of Fortive Corporation, a Delaware corporation, and Landauer, Inc., a Delaware corporation (the ?Issuer?), each outstanding share of the Issuer?s common stock was disposed of pursuant to the closing on October 19, 2017 of a cash tender offer by Purchaser to acquire common stock of Issuer in exchange for $67.25 per share in cash, subject to any required withholding of taxes, without interest.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
Hill-Rom Holdings, Inc.
Report date December 13, 2021 · Filed December 15, 2021
Section 16 reporting ended · disclosed 2021-12-15. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2021-12-13 transaction · row 1
1 source rowRow 1 · 2021-12-13 · Disposition to issuer · Disposed 5,376 · Balance 0 F1: Disposed of pursuant to the Merger Agreement between Hill-Rom Holdings, Inc., Baxter International Inc. ("Baxter"), and a wholly-owned subsidiary of Baxter (the "Merger Agreement") in exchange for a cash payment of $156.00 per share of common stock. |
| Restricted Stock Units (03/07/2014)SEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2021-12-13 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2021-12-13 · Disposition to issuer · Disposed 4,262 · Balance 0 F2: Each restricted stock unit represents a contingent right to receive one share of Hill-Rom Holdings, Inc. common stock. F3: Pursuant to the Merger Agreement, these restricted stock units, which provided for vesting on the date of grant, with delivery of the underlying shares of common stock not occurring until the later of one year and a day from the date of grant, or the six-month anniversary of the date that the director ceases to be a member of the Board of Directors of Hill-Rom Holdings, Inc., were cancelled in exchange for a cash payment of $156.00 per share of underlying common stock. |
| Restricted Stock Units (03/05/2015)SEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2021-12-13 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2021-12-13 · Disposition to issuer · Disposed 3,339 · Balance 0 F2: Each restricted stock unit represents a contingent right to receive one share of Hill-Rom Holdings, Inc. common stock. F3: Pursuant to the Merger Agreement, these restricted stock units, which provided for vesting on the date of grant, with delivery of the underlying shares of common stock not occurring until the later of one year and a day from the date of grant, or the six-month anniversary of the date that the director ceases to be a member of the Board of Directors of Hill-Rom Holdings, Inc., were cancelled in exchange for a cash payment of $156.00 per share of underlying common stock. |
| Restricted Stock Units (03/16/2016)SEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2021-12-13 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2021-12-13 · Disposition to issuer · Disposed 3,385 · Balance 0 F2: Each restricted stock unit represents a contingent right to receive one share of Hill-Rom Holdings, Inc. common stock. F3: Pursuant to the Merger Agreement, these restricted stock units, which provided for vesting on the date of grant, with delivery of the underlying shares of common stock not occurring until the later of one year and a day from the date of grant, or the six-month anniversary of the date that the director ceases to be a member of the Board of Directors of Hill-Rom Holdings, Inc., were cancelled in exchange for a cash payment of $156.00 per share of underlying common stock. |
| Restricted Stock Units (09/19/2016)SEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2021-12-13 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2021-12-13 · Disposition to issuer · Disposed 176 · Balance 0 F2: Each restricted stock unit represents a contingent right to receive one share of Hill-Rom Holdings, Inc. common stock. F3: Pursuant to the Merger Agreement, these restricted stock units, which provided for vesting on the date of grant, with delivery of the underlying shares of common stock not occurring until the later of one year and a day from the date of grant, or the six-month anniversary of the date that the director ceases to be a member of the Board of Directors of Hill-Rom Holdings, Inc., were cancelled in exchange for a cash payment of $156.00 per share of underlying common stock. |
| Restricted Stock Units (03/14/2017)SEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2021-12-13 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2021-12-13 · Disposition to issuer · Disposed 2,762 · Balance 0 F2: Each restricted stock unit represents a contingent right to receive one share of Hill-Rom Holdings, Inc. common stock. F3: Pursuant to the Merger Agreement, these restricted stock units, which provided for vesting on the date of grant, with delivery of the underlying shares of common stock not occurring until the later of one year and a day from the date of grant, or the six-month anniversary of the date that the director ceases to be a member of the Board of Directors of Hill-Rom Holdings, Inc., were cancelled in exchange for a cash payment of $156.00 per share of underlying common stock. |
| Restricted Stock Units (03/07/2018)SEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2021-12-13 transaction · row 7
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 7 · 2021-12-13 · Disposition to issuer · Disposed 2,669 · Balance 0 F2: Each restricted stock unit represents a contingent right to receive one share of Hill-Rom Holdings, Inc. common stock. F3: Pursuant to the Merger Agreement, these restricted stock units, which provided for vesting on the date of grant, with delivery of the underlying shares of common stock not occurring until the later of one year and a day from the date of grant, or the six-month anniversary of the date that the director ceases to be a member of the Board of Directors of Hill-Rom Holdings, Inc., were cancelled in exchange for a cash payment of $156.00 per share of underlying common stock. |
| Restricted Stock Units (03/06/2019)SEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2021-12-13 transaction · row 8
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 8 · 2021-12-13 · Disposition to issuer · Disposed 2,152 · Balance 0 F2: Each restricted stock unit represents a contingent right to receive one share of Hill-Rom Holdings, Inc. common stock. F3: Pursuant to the Merger Agreement, these restricted stock units, which provided for vesting on the date of grant, with delivery of the underlying shares of common stock not occurring until the later of one year and a day from the date of grant, or the six-month anniversary of the date that the director ceases to be a member of the Board of Directors of Hill-Rom Holdings, Inc., were cancelled in exchange for a cash payment of $156.00 per share of underlying common stock. |
| Restricted Stock Units (02/26/2020)SEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2021-12-13 transaction · row 9
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 9 · 2021-12-13 · Disposition to issuer · Disposed 2,263 · Balance 0 F2: Each restricted stock unit represents a contingent right to receive one share of Hill-Rom Holdings, Inc. common stock. F3: Pursuant to the Merger Agreement, these restricted stock units, which provided for vesting on the date of grant, with delivery of the underlying shares of common stock not occurring until the later of one year and a day from the date of grant, or the six-month anniversary of the date that the director ceases to be a member of the Board of Directors of Hill-Rom Holdings, Inc., were cancelled in exchange for a cash payment of $156.00 per share of underlying common stock. |
| Restricted Stock Units (03/11/2021)SEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2021-12-13 transaction · row 10
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 10 · 2021-12-13 · Disposition to issuer · Disposed 2,176 · Balance 0 F2: Each restricted stock unit represents a contingent right to receive one share of Hill-Rom Holdings, Inc. common stock. F3: Pursuant to the Merger Agreement, these restricted stock units, which provided for vesting on the date of grant, with delivery of the underlying shares of common stock not occurring until the later of one year and a day from the date of grant, or the six-month anniversary of the date that the director ceases to be a member of the Board of Directors of Hill-Rom Holdings, Inc., were cancelled in exchange for a cash payment of $156.00 per share of underlying common stock. |
Filing footnotes · ownership attribution and instrument terms
F1: Disposed of pursuant to the Merger Agreement between Hill-Rom Holdings, Inc., Baxter International Inc. ("Baxter"), and a wholly-owned subsidiary of Baxter (the "Merger Agreement") in exchange for a cash payment of $156.00 per share of common stock.
F2: Each restricted stock unit represents a contingent right to receive one share of Hill-Rom Holdings, Inc. common stock.
F3: Pursuant to the Merger Agreement, these restricted stock units, which provided for vesting on the date of grant, with delivery of the underlying shares of common stock not occurring until the later of one year and a day from the date of grant, or the six-month anniversary of the date that the director ceases to be a member of the Board of Directors of Hill-Rom Holdings, Inc., were cancelled in exchange for a cash payment of $156.00 per share of underlying common stock.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| August 07, 2007 Filed Aug 9, 2007 21:48 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | Exercise / conversionCommon shares without par value | 11,006 | $41.64 | $458,318.46 |
DisclosureSEC source: 0001104659-07-061073 · a4.xml · nonDerivative · entry 2 DEMPSEY WILLIAM G · CIK 0001239422 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 249,088 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 07, 2007 Filed Aug 9, 2007 21:48 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | Exercise / conversionCommon shares without par value | 17,053 | $41.03 | $699,713.58 |
DisclosureSEC source: 0001104659-07-061073 · a4.xml · nonDerivative · entry 1 DEMPSEY WILLIAM G · CIK 0001239422 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 238,082 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 20, 2007 Filed Feb 20, 2007 21:49 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | Tax withholdingCommon shares without par value | 3,156 | $52.49 | $165,658.44 |
DisclosureSEC source: 0001104659-07-012303 · a4.xml · nonDerivative · entry 6 DEMPSEY WILLIAM G · CIK 0001239422 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 220,064 Read SEC document |
| February 20, 2007 Filed Feb 22, 2007 23:00 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | GrantOption (right to buy) · Derivative | 6,744 | $0.00 Strike: $52.49 | $0.00 |
DisclosureSEC source: 0001104659-07-013234 · a4.xml · derivative · entry 5 DEMPSEY WILLIAM G · CIK 0001239422 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,744 Underlying: common shares · 6,744 shares Expires 2013-02-13 F2 · security: Employee stock option granted pursuant to the Abbott Laboratories 1996 Incentive Stock Program, including a replacement option feature, in a transaction exempt from Section 16(b) under Rule 16b-3. Read SEC document |
| February 20, 2007 Filed Feb 22, 2007 23:00 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | Exercise / conversionOption (right to buy) · Derivative | 7,709 | $0.00 Strike: $41.64 | $0.00 |
DisclosureSEC source: 0001104659-07-013234 · a4.xml · derivative · entry 4 DEMPSEY WILLIAM G · CIK 0001239422 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,006 Underlying: common shares · 7,709 shares Expires 2013-02-13 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · security: Employee stock option granted pursuant to the Abbott Laboratories 1996 Incentive Stock Program, including a replacement option feature, in a transaction exempt from Section 16(b) under Rule 16b-3. Read SEC document |
| February 20, 2007 Filed Feb 22, 2007 23:00 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | Tax withholdingCommon shares without par value | 6,744 | $52.49 | $353,992.56 |
DisclosureSEC source: 0001104659-07-013234 · a4.xml · nonDerivative · entry 2 DEMPSEY WILLIAM G · CIK 0001239422 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 221,029 Read SEC document |
| February 20, 2007 Filed Feb 22, 2007 23:00 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | Exercise / conversionCommon shares without par value | 7,709 | $41.64 | $321,022.80 |
DisclosureSEC source: 0001104659-07-013234 · a4.xml · nonDerivative · entry 1 DEMPSEY WILLIAM G · CIK 0001239422 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 227,773 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 18, 2007 Filed Feb 20, 2007 21:49 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | Tax withholdingCommon shares without par value | 1,222 | $52.49 | $64,142.78 |
DisclosureSEC source: 0001104659-07-012303 · a4.xml · nonDerivative · entry 5 DEMPSEY WILLIAM G · CIK 0001239422 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 223,220 Read SEC document |
| February 17, 2007 Filed Feb 20, 2007 21:49 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | Tax withholdingCommon shares without par value | 3,486 | $52.49 | $182,980.14 |
DisclosureSEC source: 0001104659-07-012303 · a4.xml · nonDerivative · entry 4 DEMPSEY WILLIAM G · CIK 0001239422 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 224,442 Read SEC document |
| February 16, 2007 Filed Feb 20, 2007 21:49 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | GrantOption (right to buy) · Derivative | 112,000 | $0.00 Strike: $52.54 | $0.00 |
DisclosureSEC source: 0001104659-07-012303 · a4.xml · derivative · entry 8 DEMPSEY WILLIAM G · CIK 0001239422 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 112,000 Underlying: common shares · 112,000 shares Expires 2017-02-15 F4 · security: Employee stock option granted pursuant to the Abbott Laboratories 1996 Incentive Stock Program in a transaction exempt from Section 16(b) under Rule 16b-3. The option becomes exercisable in annual increments of 37,334 on 2/16/08, 37,333 on 2/16/09 and 37,333 on 2/16/10. Read SEC document |
| February 16, 2007 Filed Feb 20, 2007 21:49 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | GrantCommon shares without par value | 21,000 | $52.54 | $1,103,340.00 |
DisclosureSEC source: 0001104659-07-012303 · a4.xml · nonDerivative · entry 3 DEMPSEY WILLIAM G · CIK 0001239422 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 227,928 F2 · kind: These shares represent a retention award of restricted stock under the Abbott Laboratories 1996 Incentive Stock Program. The awards generally vest on the third anniversary of their grant date and include the right to have stock withheld for tax purposes. Read SEC document |
| February 16, 2007 Filed Feb 20, 2007 21:49 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | GrantCommon shares without par value | 27,600 | $52.54 | $1,450,104.00 |
DisclosureSEC source: 0001104659-07-012303 · a4.xml · nonDerivative · entry 2 DEMPSEY WILLIAM G · CIK 0001239422 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 206,928 F1 · kind: These shares represent performance vested restricted stock awards under the Abbott Laboratories 1996 Incentive Stock Program. The awards have a 5-year term, with no more than 1/3 of the award vesting in any one year upon Abbott reaching a minimum return on equity target. The awards include the right to have stock withheld for tax purposes. Read SEC document |
| February 15, 2007 Filed Feb 20, 2007 21:49 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | Tax withholdingCommon shares without par value | 9,863 | $52.70 | $519,780.10 |
DisclosureSEC source: 0001104659-07-012303 · a4.xml · nonDerivative · entry 1 DEMPSEY WILLIAM G · CIK 0001239422 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 179,328 Read SEC document |
| February 02, 2007 Filed Feb 7, 2007 00:34 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | GrantOption (right to buy) · Derivative | 10,591 | $0.00 Strike: $52.87 | $0.00 |
DisclosureSEC source: 0001104659-07-007674 · a4.xml · derivative · entry 12 DEMPSEY WILLIAM G · CIK 0001239422 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,591 Underlying: common shares · 10,591 shares Expires 2013-02-13 F2 · security: Employee stock option granted pursuant to the Abbott Laboratories 1996 Incentive Stock Program, including a replacement option feature, in a transaction exempt from Section 16(b) under Rule 16b-3. Read SEC document |
| February 02, 2007 Filed Feb 7, 2007 00:34 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | GrantOption (right to buy) · Derivative | 44,824 | $0.00 Strike: $52.87 | $0.00 |
DisclosureSEC source: 0001104659-07-007674 · a4.xml · derivative · entry 11 DEMPSEY WILLIAM G · CIK 0001239422 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 44,824 Underlying: common shares · 44,824 shares Expires 2010-02-10 F2 · security: Employee stock option granted pursuant to the Abbott Laboratories 1996 Incentive Stock Program, including a replacement option feature, in a transaction exempt from Section 16(b) under Rule 16b-3. Read SEC document |
| February 02, 2007 Filed Feb 7, 2007 00:34 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | GrantOption (right to buy) · Derivative | 33,282 | $0.00 Strike: $52.87 | $0.00 |
DisclosureSEC source: 0001104659-07-007674 · a4.xml · derivative · entry 10 DEMPSEY WILLIAM G · CIK 0001239422 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 33,282 Underlying: common shares · 33,282 shares Expires 2014-02-19 F2 · security: Employee stock option granted pursuant to the Abbott Laboratories 1996 Incentive Stock Program, including a replacement option feature, in a transaction exempt from Section 16(b) under Rule 16b-3. Read SEC document |
| February 02, 2007 Filed Feb 7, 2007 00:34 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | Exercise / conversionOption (right to buy) · Derivative | 12,457 | $0.00 Strike: $41.64 | $0.00 |
DisclosureSEC source: 0001104659-07-007674 · a4.xml · derivative · entry 9 DEMPSEY WILLIAM G · CIK 0001239422 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,715 Underlying: common shares · 12,457 shares Expires 2013-02-13 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · security: Employee stock option granted pursuant to the Abbott Laboratories 1996 Incentive Stock Program, including a replacement option feature, in a transaction exempt from Section 16(b) under Rule 16b-3. Read SEC document |
| February 02, 2007 Filed Feb 7, 2007 00:34 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | Exercise / conversionOption (right to buy) · Derivative | 53,171 | $0.00 Strike: $41.11 | $0.00 |
DisclosureSEC source: 0001104659-07-007674 · a4.xml · derivative · entry 8 DEMPSEY WILLIAM G · CIK 0001239422 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: common shares · 53,171 shares Expires 2010-02-10 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · security: Employee stock option granted pursuant to the Abbott Laboratories 1996 Incentive Stock Program, including a replacement option feature, in a transaction exempt from Section 16(b) under Rule 16b-3. Read SEC document |
| February 02, 2007 Filed Feb 7, 2007 00:34 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | Exercise / conversionOption (right to buy) · Derivative | 39,015 | $0.00 Strike: $41.03 | $0.00 |
DisclosureSEC source: 0001104659-07-007674 · a4.xml · derivative · entry 7 DEMPSEY WILLIAM G · CIK 0001239422 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,507 Underlying: common shares · 39,015 shares Expires 2014-02-19 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · security: Employee stock option granted pursuant to the Abbott Laboratories 1996 Incentive Stock Program, including a replacement option feature, in a transaction exempt from Section 16(b) under Rule 16b-3. Read SEC document |
| February 02, 2007 Filed Feb 7, 2007 00:34 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | Tax withholdingCommon shares without par value | 88,697 | $52.87 | $4,689,410.39 |
DisclosureSEC source: 0001104659-07-007674 · a4.xml · nonDerivative · entry 4 DEMPSEY WILLIAM G · CIK 0001239422 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 191,744 Read SEC document |
| February 02, 2007 Filed Feb 7, 2007 00:34 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | Exercise / conversionCommon shares without par value | 12,457 | $41.64 | $518,741.87 |
DisclosureSEC source: 0001104659-07-007674 · a4.xml · nonDerivative · entry 3 DEMPSEY WILLIAM G · CIK 0001239422 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 280,441 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 02, 2007 Filed Feb 7, 2007 00:34 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | Exercise / conversionCommon shares without par value | 53,171 | $41.11 | $2,185,694.98 |
DisclosureSEC source: 0001104659-07-007674 · a4.xml · nonDerivative · entry 2 DEMPSEY WILLIAM G · CIK 0001239422 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 267,984 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 02, 2007 Filed Feb 7, 2007 00:34 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | Exercise / conversionCommon shares without par value | 39,015 | $41.03 | $1,600,851.78 |
DisclosureSEC source: 0001104659-07-007674 · a4.xml · nonDerivative · entry 1 DEMPSEY WILLIAM G · CIK 0001239422 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 214,813 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| January 29, 2007 Filed Feb 1, 2007 01:35 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | Exercise / conversionOption (right to buy) · Derivative | 22,916 | $0.00 Strike: $48.67 | $0.00 |
DisclosureSEC source: 0001104659-07-006236 · a4.xml · derivative · entry 8 DEMPSEY WILLIAM G · CIK 0001239422 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: common shares · 22,916 shares Expires 2007-02-13 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · security: Employee stock option granted pursuant to the Abbott Laboratories 1996 Incentive Stock Program, in a transaction exempt from Section 16(b) under Rule 16b-3. Read SEC document |
| January 29, 2007 Filed Feb 1, 2007 01:35 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | Exercise / conversionOption (right to buy) · Derivative | 2,278 | $0.00 Strike: $43.86 | $0.00 |
DisclosureSEC source: 0001104659-07-006236 · a4.xml · derivative · entry 7 DEMPSEY WILLIAM G · CIK 0001239422 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: common shares · 2,278 shares Expires 2007-02-13 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · security: Employee stock option granted pursuant to the Abbott Laboratories 1996 Incentive Stock Program, in a transaction exempt from Section 16(b) under Rule 16b-3. Read SEC document |
| January 29, 2007 Filed Feb 1, 2007 01:35 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | Exercise / conversionOption (right to buy) · Derivative | 5,570 | $0.00 Strike: $50.38 | $0.00 |
DisclosureSEC source: 0001104659-07-006236 · a4.xml · derivative · entry 6 DEMPSEY WILLIAM G · CIK 0001239422 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: common shares · 5,570 shares Expires 2007-02-13 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · security: Employee stock option granted pursuant to the Abbott Laboratories 1996 Incentive Stock Program, in a transaction exempt from Section 16(b) under Rule 16b-3. Read SEC document |
| January 29, 2007 Filed Feb 1, 2007 01:35 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | SaleCommon shares without par value | 30,764 | $52.67 | $1,620,290.66 |
DisclosureSEC source: 0001104659-07-006236 · a4.xml · nonDerivative · entry 4 DEMPSEY WILLIAM G · CIK 0001239422 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 175,798 Read SEC document |
| January 29, 2007 Filed Feb 1, 2007 01:35 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | Exercise / conversionCommon shares without par value | 22,916 | $48.67 | $1,115,321.72 |
DisclosureSEC source: 0001104659-07-006236 · a4.xml · nonDerivative · entry 3 DEMPSEY WILLIAM G · CIK 0001239422 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 206,562 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| January 29, 2007 Filed Feb 1, 2007 01:35 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | Exercise / conversionCommon shares without par value | 2,278 | $43.86 | $99,913.08 |
DisclosureSEC source: 0001104659-07-006236 · a4.xml · nonDerivative · entry 2 DEMPSEY WILLIAM G · CIK 0001239422 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 183,646 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| January 29, 2007 Filed Feb 1, 2007 01:35 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | Exercise / conversionCommon shares without par value | 5,570 | $50.38 | $280,631.64 |
DisclosureSEC source: 0001104659-07-006236 · a4.xml · nonDerivative · entry 1 DEMPSEY WILLIAM G · CIK 0001239422 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 181,368 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| December 01, 2006 Filed Feb 7, 2007 00:34 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | GiftCommon shares without par value | 2,553 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-07-007674 · a4.xml · nonDerivative · entry 5 DEMPSEY WILLIAM G · CIK 0001239422 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 189,191 Read SEC document |
| November 01, 2006 Filed Nov 3, 2006 22:01 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | GrantCommon shares without par value | 20,000 | $47.36 | $947,200.00 |
DisclosureSEC source: 0001104659-06-071267 · a4.xml · nonDerivative · entry 1 DEMPSEY WILLIAM G · CIK 0001239422 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 175,798 F1 · kind: These shares represent a restricted stock award under the Abbott Laboratories 1996 Incentive Stock Program in a transaction exempt from Section 16(b) under Rule 16b-3. The award includes the right to have stock withheld for tax purposes. Read SEC document |
| August 16, 2006 Filed Aug 18, 2006 16:17 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | GrantOption (right to buy) · Derivative | 2,082 | $0.00 Strike: $48.66 | $0.00 |
DisclosureSEC source: 0001104659-06-056022 · a4.xml · derivative · entry 8 DEMPSEY WILLIAM G · CIK 0001239422 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,082 Underlying: common shares · 2,082 shares Expires 2013-02-13 F2 · security: Employee stock option granted pursuant to the Abbott Laboratories 1996 Incentive Stock Program, including a replacement option feature, in a transaction exempt from Section 16(b) under Rule 16b-3. Read SEC document |
| August 16, 2006 Filed Aug 18, 2006 16:17 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | GrantOption (right to buy) · Derivative | 2,054 | $0.00 Strike: $48.66 | $0.00 |
DisclosureSEC source: 0001104659-06-056022 · a4.xml · derivative · entry 7 DEMPSEY WILLIAM G · CIK 0001239422 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,054 Underlying: common shares · 2,054 shares Expires 2010-02-10 F2 · security: Employee stock option granted pursuant to the Abbott Laboratories 1996 Incentive Stock Program, including a replacement option feature, in a transaction exempt from Section 16(b) under Rule 16b-3. Read SEC document |
| August 16, 2006 Filed Aug 18, 2006 16:17 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | Exercise / conversionOption (right to buy) · Derivative | 3,050 | $0.00 Strike: $33.23 | $0.00 |
DisclosureSEC source: 0001104659-06-056022 · a4.xml · derivative · entry 6 DEMPSEY WILLIAM G · CIK 0001239422 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: common shares · 3,050 shares Expires 2013-02-13 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · security: Employee stock option granted pursuant to the Abbott Laboratories 1996 Incentive Stock Program, including a replacement option feature, in a transaction exempt from Section 16(b) under Rule 16b-3. Read SEC document |
| August 16, 2006 Filed Aug 18, 2006 16:17 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | Exercise / conversionOption (right to buy) · Derivative | 3,065 | $0.00 Strike: $32.61 | $0.00 |
DisclosureSEC source: 0001104659-06-056022 · a4.xml · derivative · entry 5 DEMPSEY WILLIAM G · CIK 0001239422 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: common shares · 3,065 shares Expires 2010-02-10 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · security: Employee stock option granted pursuant to the Abbott Laboratories 1996 Incentive Stock Program, including a replacement option feature, in a transaction exempt from Section 16(b) under Rule 16b-3. Read SEC document |
| August 16, 2006 Filed Aug 18, 2006 16:17 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | Tax withholdingCommon shares without par value | 4,136 | $48.66 | $201,257.76 |
DisclosureSEC source: 0001104659-06-056022 · a4.xml · nonDerivative · entry 3 DEMPSEY WILLIAM G · CIK 0001239422 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 155,798 Read SEC document |
| August 16, 2006 Filed Aug 18, 2006 16:17 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | Exercise / conversionCommon shares without par value | 3,050 | $33.23 | $101,355.77 |
DisclosureSEC source: 0001104659-06-056022 · a4.xml · nonDerivative · entry 2 DEMPSEY WILLIAM G · CIK 0001239422 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 159,934 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 16, 2006 Filed Aug 18, 2006 16:17 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | Exercise / conversionCommon shares without par value | 3,065 | $32.61 | $99,953.02 |
DisclosureSEC source: 0001104659-06-056022 · a4.xml · nonDerivative · entry 1 DEMPSEY WILLIAM G · CIK 0001239422 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 156,884 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 21, 2006 Filed Feb 22, 2006 22:42 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | SaleCommon shares without par value | 310 | $43.79 | $13,574.90 |
DisclosureSEC source: 0001104659-06-011225 · a4.xml · nonDerivative · entry 3 DEMPSEY WILLIAM G · CIK 0001239422 · Senior Vice Pesident 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 153,819 Read SEC document |
| February 18, 2006 Filed Feb 22, 2006 22:42 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | Tax withholdingCommon shares without par value | 1,080 | $44.15 | $47,682.00 |
DisclosureSEC source: 0001104659-06-011225 · a4.xml · nonDerivative · entry 1 DEMPSEY WILLIAM G · CIK 0001239422 · Senior Vice Pesident 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 127,629 Read SEC document |
| February 17, 2006 Filed Feb 22, 2006 22:42 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | GrantOption (right to buy) · Derivative | 83,000 | $0.00 Strike: $44.16 | $0.00 |
DisclosureSEC source: 0001104659-06-011225 · a4.xml · derivative · entry 5 DEMPSEY WILLIAM G · CIK 0001239422 · Senior Vice Pesident 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 83,000 Underlying: common shares · 83,000 shares Expires 2016-02-16 F3 · security: Employee stock option granted pursuant to the Abbott Laboratories 1996 Incentive Stock Program in a transaction exempt from Section 16(b) Rule 16b-3. The option becomes exercisable in annual increments of 27,667 on 2/17/2007, 27,667 on 2/17/2008 and 27,666 on 2/17/2009. Read SEC document |
| February 17, 2006 Filed Feb 22, 2006 22:42 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | GrantCommon shares without par value | 26,500 | $44.16 | $1,170,240.00 |
DisclosureSEC source: 0001104659-06-011225 · a4.xml · nonDerivative · entry 2 DEMPSEY WILLIAM G · CIK 0001239422 · Senior Vice Pesident 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 154,129 F1 · kind: These shares represent performance vested restricted stock awards under the Abbott Laboratories 1996 Incentive Stock Program in a transaction exempt from Section 16(b) under Rule 16b-3. The awards have a 5-year term, with no more than 1/3 of the award vesting in any one year upon Abbott reaching a minimum return on equity target. The awards include the right to have stock withheld for tax purposes. Read SEC document |
| February 14, 2006 Filed Feb 17, 2006 00:14 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | GrantOption (right to buy) · Derivative | 27,328 | $0.00 Strike: $42.83 | $0.00 |
DisclosureSEC source: 0001104659-06-010256 · a4.xml · derivative · entry 6 DEMPSEY WILLIAM G · CIK 0001239422 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 27,328 Underlying: common shares · 27,328 shares Expires 2013-02-13 F2 · security: Employee stock option granted pursuant to the Abbott Laboratories 1996 Incentive Stock Program, including a replacement option feature, in a transaction exempt from Section 16(b) under Rule 16b-3. Read SEC document |
| February 14, 2006 Filed Feb 17, 2006 00:14 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | Exercise / conversionOption (right to buy) · Derivative | 32,418 | $0.00 Strike: $33.23 | $0.00 |
DisclosureSEC source: 0001104659-06-010256 · a4.xml · derivative · entry 5 DEMPSEY WILLIAM G · CIK 0001239422 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,050 Underlying: common shares · 32,418 shares Expires 2013-02-13 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · security: Employee stock option granted pursuant to the Abbott Laboratories 1996 Incentive Stock Program, including a replacement option feature, in a transaction exempt from Section 16(b) under Rule 16b-3. Read SEC document |
| February 14, 2006 Filed Feb 17, 2006 00:14 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | SaleCommon shares without par value | 713 | $43.70 | $31,158.10 |
DisclosureSEC source: 0001104659-06-010256 · a4.xml · nonDerivative · entry 3 DEMPSEY WILLIAM G · CIK 0001239422 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 128,709 Read SEC document |
| February 14, 2006 Filed Feb 17, 2006 00:14 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | Tax withholdingCommon shares without par value | 27,328 | $42.83 | $1,170,458.24 |
DisclosureSEC source: 0001104659-06-010256 · a4.xml · nonDerivative · entry 2 DEMPSEY WILLIAM G · CIK 0001239422 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 129,422 Read SEC document |
| February 14, 2006 Filed Feb 17, 2006 00:14 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | Exercise / conversionCommon shares without par value | 32,418 | $33.23 | $1,077,295.53 |
DisclosureSEC source: 0001104659-06-010256 · a4.xml · nonDerivative · entry 1 DEMPSEY WILLIAM G · CIK 0001239422 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 156,750 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| December 21, 2005 Filed Feb 9, 2006 21:50 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | GiftCommon shares without par value | 2,894 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-06-007437 · a5.xml · nonDerivative · entry 1 DEMPSEY WILLIAM G · CIK 0001239422 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 124,332 Read SEC document |
| October 04, 2005 Filed Oct 5, 2005 21:53 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | Exercise / conversionOption (right to buy) · Derivative | 2,385 | $0.00 Strike: $41.90 | $0.00 |
DisclosureSEC source: 0001104659-05-047342 · a4.xml · derivative · entry 12 DEMPSEY WILLIAM G · CIK 0001239422 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: common shares · 2,385 shares Expires 2006-02-08 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · security: Employee stock option granted pursuant to the Abbott Laboratories 1996 Incentive Stock Program, including a replacement option feature, in a transaction exempt from Section 16(b) under Rule 16b-3. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.